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COriginal article 241Effect of device-guided breathing exercises on blood
pressure in hypertensive patients with type 2 diabetes
mellitus: a randomized controlled trial
Susan J. Logtenberga, Nanne Kleefstraa,b, Sebastiaan T. Houwelingb,
Klaas H. Groenierc and Henk J. Biloa,bObjective In patients with type 2 diabetes mellitus (DM2), it
is hard to reach treatment objectives for blood pressure
(BP) with classical treatment options. Recently, reducing
breathing frequency has been advocated as a method to
reduce BP. We examined if an electronic device such as
Resperate, by reducing breathing frequency, would lead to
BP reduction in a population of patients with DM2 and
hypertension. Our secondary objective was to study the
effect of this device on quality of life (QOL).
Methods A randomized, single-blind, controlled trial was
conducted over a period of 8 weeks to evaluate the effect of
this therapy on BP and QOL. The control group listened to
music and used no other therapeutic device. BP and QOL
changes were studied in 30 patients with DM2 and
hypertension.
Results There was no significant difference in change in BP
between groups; S7.5 [95% confidence interval (CI) S12.7,
S2.3]/S1.0 (95% CI S5.5, 3.6) mmHg in the intervention
group and S12.2 (95% CI S17.4, S7.0)/S5.5 (95% CI S9.7,
S1.4) mmHg in the control group. Whether or not the target
breathing frequency of 10 breaths/min was reached did not
affect BP. There were no significant changes in QOL.opyright © Lippincott Williams & Wilkins. Unauth
0263-6352  2007 Lippincott Williams & WilkinsConclusions The effects of Resperate on BP and QOL were
not significantly different from those found in the control
group. Furthermore, 40% of patients did not reach the target
breathing frequency, making this device less suitable for
clinical practice in patients with DM2. J Hypertens 25:241–
246 Q 2007 Lippincott Williams & Wilkins.
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Diabetes mellitus type 2 (DM2) and hypertension
commonly occur together, with a higher prevalence of
hypertension in patients with DM2 than in the general
population [1]. Prevalence of hypertension in diabetes
patients was 39% in the Hypertension in Diabetes
Study (HDS) [1]. In The Netherlands a prevalence of
hypertension in the general population (20–70 years) of
27% for men and 22% for women was found (this
percentage includes persons taking antihypertensive
drugs) [2].
The United Kingdom Prospective Diabetes Study
(UKPDS) showed that tight blood pressure (BP) control
in patients with hypertension and DM2 results in a
clinically important reduction of morbidity and mortality
[3]. Both DM2 and hypertension have a negative impact
on quality of life (QOL) [4].
Standard treatments of hypertension consist of a com-
bination of pharmacological and non-pharmacologicalregimens. The UKPDS showed that in patients with
DM2 two or more antihypertensive drugs are often
required to attain BP goals [3]. Recently, a new non-
pharmacological treatment has been proposed, consisting
of breathing exercises guided by an electronic device; the
Resperate (InterCure Ltd, Lod, Israel) [5]. The exercises
are said to be successful if breathing frequency is less than
10 breaths/min at the end of the exercise. Exercises should
be done daily for 10–15 min [5–9]. The rationale behind
this therapy is that slow and regular breathing increases the
baroreflex sensitivity, which can reduce autonomic imbal-
ance. Autonomic imbalance is thought to be an important
factor in the development of hypertension [10].
Studies with this device done so far report a significant
reduction in BP after 8 weeks in hypertensive patients
with or without the addition of antihypertensive drugs
[5–9,11]. These studies had either no active control
group or a control group that listened to music through
a Walkman. Diabetes mellitus was an exclusion criterion
in three studies [5,7,8].orized reproduction of this article is prohibited.
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efficacy of this non-pharmacological therapy by compar-
ing its effects to the effects of listening to music with a
Discman on BP and QOL in a population of patients with
DM2 and moderate controlled BP.
Methods
Participants
Patients were recruited from the outpatient clinic of the
Isala Clinics in Zwolle, The Netherlands. Eligibility
criteria were: age over 18 years, diagnosis of DM2 more
than 2 years ago, use of at least one antihypertensive drug
without changes in the past 3 months, a systolic BP
between 130 and 170 mmHg over the previous 6 months,
and a systolic BP between 140 and 160 mmHg at the first
study visit. Exclusion criteria were hospitalization in the
past 3 months, deafness, blindness and cognitive abilities
deemed insufficient for operation of a study device.
A letter containing information about the study and an
invitation to participate was sent to 83 patients. Based on
this information, 31 patients refused participation and
52 patients agreed to a first study visit. At this visit,
20 patients did not meet the BP inclusion criteria,
one patient was excluded because of not taking any anti-
hypertensive drugs at the time of the study visit, and
anotherpatientrefusedparticipationat thefirstvisit.Thirty
patients met all the criteria and entered the study. All
patients gave informed consent. The study was approved
by the Medical Ethics Committee of the Isala Clinics.
Recruitment took place in the first half of 2005, with the
starting point of the study being the date of recruitment.
Outcome measures, randomization and study design
The primary outcome measures were change in office and
home BP. The secondary outcome measure was change
in QOL.
Randomization was done using sealed non-transparent
envelopes, which contained an ‘I’ or ‘C’, indicating the
intervention and control group, respectively. Randomiz-
ation took place prior to the first visit.
There were two study groups. The intervention group
used the breathing device and the control group used a
Discman with various kinds of random music. All patients
were informed that the objective of the study was to
compare different types of music therapy. In addition,
patients in the intervention group were informed about
the possible effect of slow breathing guided by music.
None of the patients were informed about the treatment
in the other study group. All data were entered in a
database in duplicate by an independent third party, to
minimize typing errors.
Patients visited the clinic twice. During the first visit
patients were seen by the investigator for baselineopyright © Lippincott Williams & Wilkins. Unauthomeasurements including BP, heart rate, height and
weight (without coat and shoes), smoking status and
QOL. The trial was explained to them, and all instruc-
tions were given both verbally and in writing. The
patients were instructed in the use of the BP device
and the breathing device or the Discman. Patients were
asked to do the exercise every day for 56 days at
approximately the same time and to measure their BP
four times daily; twice within 5 min prior to and twice
within 5 min following the exercise. The second visit to
the clinic was 8 weeks after the initial visit. Patients
were seen by the same investigator. Clinical measure-
ments were again taken and the QOL questionnaire was
filled out. Furthermore, questions about knowledge of
other study participants or the other study group were
asked, to test blinding. Data of the daily home BP and
heart rate measurements, which had been written down
by each patient in a study diary, were collected from the
patients. Compliance with interventions was checked
using the ratio between the actual number of treatment
sessions performed and the requested number of sessions.
Blood pressure measurement
BP was measured both in the clinic and at home accord-
ing to the Guidelines of the Dutch Institute for Health-
care Improvement (CBO) using an Omron M5-I (HEM-
757; CEMEX Medical Technics, Nieuwegein, The
Netherlands) automatic BP device [12,13]. Use of an
automatic device prevents observer bias. Before BP
measurement during the first study visit, the circumfer-
ence of the upper arm was measured. When the circum-
ference was 22–32 cm, the standard cuff (12 21.5 cm)
was used. The large cuff (15 29.5 cm) was used
when the circumference was between 32 and 42 cm.
The measurements were done with the patient in a
sitting position, after he or she had been sitting for a
minimum of 5 min, with the cuff at heart level and the
volar side of the lower arm resting on the desk. The cuff
was applied to the bare arm 1–2 cm above the elbow fold.
Any tight clothing was removed from the upper arm. The
patient was asked to sit still, not to move the arm, and not
to speak during measurement. The time between suc-
cessive measurements was at least 15 s. Initially, the BP
was measured twice on each arm. The mean of the two
readings for the left arm was compared with the mean of
the two readings for the right arm. When there was a
difference of >10 mmHg of the systolic and/or diastolic
BP between the two arms, future measurements were
done on the arm with the higher BP. When the difference
was less, an arbitrary arm was taken for all next measure-
ments. For all analyses the mean of the two consecutive
measurements was used.
Quality of life measurement
Patients filled out a QOL questionnaire containing the
Dutch versions of the 12-item Short Form Health Survey
(SF-12), the Problem Areas in Diabetes Scale (PAID) andrized reproduction of this article is prohibited.
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Fig. 1
Assessed for eligibility (n = 83) 
Excluded (n = 53) 
Not meeting inclusion 
criteria (n = 22) 
Refused to participate 
(n = 31)
Randomized (n = 30)
Allocated to 
Resperate (n = 15) 
Allocated to 
Discman (n = 15) 
Lost to follow-up 
(n = 0) 
Lost to follow-up 
(n = 0)
Analysed (n = 15) Analysed (n = 15) 
CONSORT flow diagram, reproduced from [19]. Number of
participants in stages of the trial.





Age (years) 62.76.0 61.07.5
Male (%) 3 (20) 10 (67)
BMI (kg/m2) 31.54.7 32.55.4
Systolic BP (mmHg) 153.57.5 150.48.2
Diastolic BP (mmHg) 83.06.7 87.08.3











Values are meanSD or number (%). SD, standard deviation; BMI, body mass
index; bpm, beats per minute; BP, blood pressure; QOL, Quality of Life; PAID,
Problem Areas In Diabetes; SF-12, 12-item Short Form Health Survey; PCS,
physical component score; MCS, mental component score; WHO-5, World
Health Organization Wellbeing Scale. a Median (p25;p75) is given for a variable
with non-normal distribution. b One PAID score could not be calculated because
one patient left one question unanswered.the WHO five-item Wellbeing Index (WHO-5) [14–18].
The SF-12 is a generic measure of health-related QOL. It
is a reliable and validated short version of the SF-36
[14,15]. A physical component score (PCS) and a mental
component score (MCS) can be calculated, with higher
values representing better QOL (norm-based scores are
standardized to a mean of 50 and standard deviation of
10). The PAID is a diabetes-specific 20-item question-
naire to score diabetes-related emotional distress. It is
scored on a scale of 0 to 100, with higher scores indicating
greater emotional distress. Reliability and validity are
good for both the US and Dutch situations [16,17].
The WHO-5 measures psychological well-being in the
general population. It has a score ranging from 0 to 100,
with 0 representing worst possible and 100 representing
best possible quality of life [18].
Statistical analysis
Statistical analyses were carried out using SPSS version
12.0.1 (SPSS Inc., Chicago, Illinois, USA). A significance
level of 5% was used. As appropriate, parametric (Stu-
dent’s t) and non-parametric (Mann–Whitney U) tests
were used to compare outcome measures between
groups. The chi-squared test was applied for categorical
variables. Baseline values and end-of-treatment values
for home measurements of BP and heart rate were
calculated by averaging the pre-exercise data of the first
week (baseline) and the last week (end of treatment).
Furthermore, change of home BP measurements over
time was estimated by the linear regression coefficient for
each patient and differences in mean regression coeffi-
cients between groups were tested using Student’s t tests.
Analyses were by intention-to-treat principle. An
additional intra-group analysis of the data was carried
out to compare office BP of the patients who succeeded in
achieving the target breathing rate (< 10 breaths/min)
with those who did not.
The sample size required to detect an absolute reduction
of 10 mmHg in systolic BP during the 8-week study with
a power of 95%, and alpha 5% (two-tailed), was 28 (14 in
the intervention group and 14 in the control group). This
calculation was based on the mean systolic BP of patients
with a systolic BP between 140 and 160 mmHg in our
clinic being 148.3 6.9 mmHg.
The report was written based on the ‘Consolidation of the
standards of reporting trials’ (CONSORT) [19].
Results
Figure 1 shows the number of participants involved
throughout the trial. Baseline characteristics of the
patient population (n¼ 30) are listed in Table 1. These
characteristics are comparable between the groups;
there were more men in the control group (10 versus
three in the intervention group).opyright © Lippincott Williams & Wilkins. UnauthBlood pressure
Office systolic BP was significantly reduced at the end of
the study in both the intervention and the control group
[intervention, from 153.5 to 146.0 mmHg (P¼ 0.008);
control, from 150.4 to 138.2 mmHg (P< 0.001)]. The
office diastolic BP was significantly lower only in
the control group [intervention, from 83.0 to 82.1 mmHg
(P¼ 0.657); control, from 87.0 to 81.5 mmHg (P¼ 0.012)].orized reproduction of this article is prohibited.
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Table 2 Change in office measurements of blood pressure (BP) and heart rate after 8 weeks
Treatment group
P a Difference between groupsIntervention Control
Change in
Systolic BP (mmHg) 7.5 (12.7, 2.3) 12.2 (17.4, 7.0) 0.86 4.7 (11.7, 2.3)
Diastolic BP (mmHg) 1.0 (5.5, 3.6) 5.5 (9.7, 1.4) 0.94 4.6 (10.4, 1.3)
Heart rate (bpm) 1.7 (6.3, 2.9) 1.9 (9.2, 5.4) 0.97 0.2 (8.5, 8.1)
Values are mean (95% confidence interval). a P value of comparison between groups after 8 weeks.There were no significant differences in change of office
BP between the two groups (Table 2).
There were no significant differences in change of home
BP measurements between the two groups (Table 3).
Mean regression coefficients of the home BP measure-
ments over time were small for both groups (ranging from
0.05 to 0.12 in the intervention group and 0.09
to 0.19 in the control group), indicating a minimal
reduction of BP over time in the home setting. There
were no significant differences between the intervention
and control groups (data not shown).
Mean breathing frequency at the end of the daily exercise
in the intervention group was 10.8 6.7 breaths/min. A
post-hoc analysis in the intervention group was carried
out to test the difference in office BP between the nine
patients who reached the target breathing frequency of
10 breaths/min and the six who did not. The mean
breathing frequency was 6.2 1.9 breaths/min in the first
group and 17.7 5.0 breaths/min in the latter. BP change
was not significantly different between both groups; BP
change was 5.5 [95% confidence interval (CI) 12.9,
1.9]/0.5 (95% CI 6.5, 7.5) mmHg in the group that did
reach the breathing frequency target and 10.5 (95% CIopyright © Lippincott Williams & Wilkins. Unautho




Systolic BP (mmHg) 7.8 (12.6, 3.0) 8.8 (
Diastolic BP (mmHg) 3.3 (6.7, 0.0) 4.7 (
Heart rate (bpm) 0.2 (3.0, 3.4) 1.9 (
Values are mean (95% confidence interval). a P value of comparison between group




SF-12 PCS 0.2 (2.5, 2.2) 3.3 (1.4
SF-12 MCS 1.2 (2.7, 5.1) 1.4 (3.8
PAID 2.4 (5.3, 0.5) 2.2 (4.8
WHO-5 4.5 (5.3, 14.4) 4.0 (19.
Values are mean (95% confidence interval). SF-12, 12-item Short Form Health Survey;
Areas In Diabetes; WHO-5, World Health Organization Wellbeing Scale. a P value o19.6, 1.3)/3.2 (95% CI 10.4, 4.1) mmHg in the
group that did not (P¼ 0.33 for systolic BP change and
P¼ 0.42 for diastolic BP change).
Heart rate
Office heart rate did not change in either group [interven-
tion, from 73.7 to 72.0 beats/min (bpm) (P¼ 0.44); control,
from 78.5 to 76.7 bpm (P¼ 0.59)]. There were no signifi-
cant differences in change of office heart rate between
the two groups (Table 2). There was no significant differ-
ence in change of home measurements of heart rate
between the intervention and control group (Table 3).
Quality of life
Table 4 shows that QOL did not change significantly over
time, nor did it differ between the intervention and
control groups.
Blinding and compliance
The questionnaire at 8 weeks showed that blinding was
successful. No adverse events or side effects were
reported. Compliance with therapy was high, with more
than 90% of recommended daily sessions done by all
patients in both groups (94% in intervention and control
group).rized reproduction of this article is prohibited.
heart rate
P a Difference between groupsControl
14.1, 3.5) 0.77 1.0 (7.8, 5.8)
8.0, 1.3) 0.55 1.3 (5.8, 3.2)
0.5, 4.3) 0.37 1.7 (2.1, 5.5)
s after 8 weeks.
P a Difference between groupsol
, 8.0) 0.17 3.5 (1.6, 8.5)
, 6.7) 0.94 0.2 (6.0, 6.5)
, 9.3) 0.19 4.6 (2.7, 12.1)
6, 11.6) 0.33 8.5 (26.2, 9.1)
PCS, physical component score; MCS, mental component score; PAID, Problem
f comparison between groups after 8 weeks.
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This study shows that breathing exercises guided by an
electronic device do not reduce BP in patients with DM2,
as measured both in the clinic and at home, to a greater
extent than listening to music on a Discman. We chose
listening to music with a Discman as our control group to
keep the interventions in both groups as similar as
possible with the exception of the active lowering of
breathing frequency in the intervention group.
Several clinical trials have shown that listening to music
can lower BP. This is mostly investigated in a periopera-
tive setting or in patients undergoing endoscopic pro-
cedures [20–23]. Because of this effect, choosing music as
our control group enabled us to differentiate between the
effect of listening to music (the Resperate produces
musical tones as well) and the effect of reducing breath-
ing frequency on BP.
Our study shows that we cannot attribute the effect on
BP seen in the intervention group to the reduction of
breathing frequency achieved with the device. However,
only a small number of subjects were able to reduce their
breathing frequency. Therefore, the question remains
unanswered whether the failure to observe any effect on
BP is due to lack of efficacy of the device, or due to the
inability of our subjects to reach sufficiently low breath-
ing frequencies. Our results do not support findings
reported previously. To our knowledge, this is the first
study of its kind done in patients with DM2. Grossman
et al. [5] and Schein et al. [7] studied the effect in
hypertensive patients, either with or without antihyper-
tensive drug therapy, and used listening to music
through a Walkman as their control group. Both reported
significant BP reductions in the intervention group as
compared to the control group: 7.5/4.0 versus 2.9/
1.5 mmHg (P¼ 0.001, P¼ 0.12) and 15.2/10.0 ver-
sus 11.3/5.6 mmHg (P¼ 0.14, P¼ 0.008), respect-
ively. Meles et al. [9] and Elliot et al. [11] used no
device in their control groups and both reported signifi-
cant decreases in systolic or diastolic BP in their inter-
vention groups [Meles et al.: 5.5/3.6 versus 0.2/
þ0.9 mmHg (NS, P< 0.05); Elliot et al.: systolic BP
15.0 versus 9.2 mmHg (P¼ 0.012)]. Rosenthal et al.
[6] and Viskoper et al. [8] did not have control groups, but
reported significant decreases in BP at 8 weeks: 7.2/
3.4 mmHg (P< 0.01, NS) and 12.9/6.9 mmHg
(P< 0.001 for both), respectively. In our opinion, using
an active control in our study contributed to a more
reliable outcome.
Hypertension is a multifactorial condition and in
patients with DM2, as compared to non-diabetic sub-
jects, other factors might be involved in eliciting hyper-
tension. Moreover, consequences of the longstanding
presence of DM2 and hypertension might play a role
both in the severity of hypertension and its sequelae,opyright © Lippincott Williams & Wilkins. Unauthand the possibilities to correct raised BP. For example,
reduced baroreflex sensitivity (BRS) is an indicator of
increased risk for mortality and morbidity and is associ-
ated independently with both diabetes mellitus and
hypertension [24,25]. However, no measurements of
BRS were done in the present or previous studies,
and therefore we cannot conclude that having DM2
per se was the reason for our negative results. Having
performed these measurements would possibly have
given us important information.
In our study, nine of the 15 patients in the intervention
group succeeded in lowering their breathing rates to the
target of less than 10 breaths/min. This was despite the
verbal and written instructions, repeated as necessary, with
which the patient was provided. This makes Resperate
therapy less attractive for use in clinical practice in patients
with DM2. Not only are there questions about the efficacy
of this device, only 60% of patients will achieve the
breathing rates reported to maximize the effects of this
treatment.
More research is needed to study the effects of both
music and breathing techniques on BP. To eliminate
bias, an independent double-blind study should be car-
ried out in which the intervention and the control groups
use the same device, with the only difference being that
in the intervention group, but not in the control group,
the breathing frequency can be altered (< 10 breaths/
min). Furthermore, breathing frequency of the control
group should be monitored. Baroreceptor reflex sensi-
tivity and carotid intima–media thickness should be
important parameters in every follow-up study.
We could not measure an effect on QOL with either
intervention. The duration of the study may have been of
insufficient length and scope to detect measurable
changes in QOL. Moreover, hypertension, a condition
often lacking symptoms, may have less of an effect on
QOL than, for example, diabetes itself.
In conclusion, the effects of reducing breathing fre-
quency with the Resperate on BP and QOL were not
different from those found in the control group, and a
large proportion (40%) of patients with DM2 did not
reach the target breathing frequency, making this device
less suitable for clinical practice in patients with DM2.
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